Williams A J, Baker F E, Walls J
J Pharm Pharmacol. 1985 Oct;37(10):741-3. doi: 10.1111/j.2042-7158.1985.tb04957.x.
The effects of bezafibrate on hyperlipidaemia in experimental nephrotic syndrome in rats has been investigated. The treated group received bezafibrate 10 mg kg-1 p.o. daily. No significant differences in total serum cholesterol occurred, but a significant reduction in serum triglyceride (P less than 0.005) and elevation in HDL cholesterol (P less than 0.005) occurred. These findings may have implications for therapeutic intervention in severe hyperlipidaemia of the nephrotic syndrome in man.
已对苯扎贝特对大鼠实验性肾病综合征高脂血症的影响进行了研究。治疗组每日口服苯扎贝特10mg/kg。血清总胆固醇无显著差异,但血清甘油三酯显著降低(P<0.005),高密度脂蛋白胆固醇升高(P<0.005)。这些发现可能对人类肾病综合征严重高脂血症的治疗干预具有启示意义。